nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—PSIP1—myometrium—uterine cancer	0.0126	0.0553	CbGeAlD
L-DOPA—Mimosine—CCL2—uterine cancer	0.00995	0.538	CrCbGaD
L-DOPA—PSIP1—uterine cervix—uterine cancer	0.00981	0.043	CbGeAlD
L-DOPA—PSIP1—decidua—uterine cancer	0.00934	0.041	CbGeAlD
L-DOPA—PSIP1—renal system—uterine cancer	0.00917	0.0403	CbGeAlD
L-DOPA—PSIP1—endometrium—uterine cancer	0.00887	0.0389	CbGeAlD
L-DOPA—PSIP1—mammalian vulva—uterine cancer	0.00858	0.0377	CbGeAlD
L-DOPA—PSIP1—uterus—uterine cancer	0.00817	0.0359	CbGeAlD
L-DOPA—PSIP1—female reproductive system—uterine cancer	0.00735	0.0322	CbGeAlD
L-DOPA—PSIP1—female gonad—uterine cancer	0.00668	0.0293	CbGeAlD
L-DOPA—PSIP1—vagina—uterine cancer	0.00664	0.0292	CbGeAlD
L-DOPA—Masoprocol—IGF1R—uterine cancer	0.00649	0.351	CrCbGaD
L-DOPA—SLC7A5—myometrium—uterine cancer	0.00644	0.0282	CbGeAlD
L-DOPA—PSIP1—Teniposide—Etoposide—uterine cancer	0.00642	0.422	CbGdCrCtD
L-DOPA—PSIP1—Podofilox—Etoposide—uterine cancer	0.00642	0.422	CbGdCrCtD
L-DOPA—SLC7A8—decidua—uterine cancer	0.00616	0.027	CbGeAlD
L-DOPA—SLC7A8—renal system—uterine cancer	0.00605	0.0265	CbGeAlD
L-DOPA—DDC—renal system—uterine cancer	0.00523	0.023	CbGeAlD
L-DOPA—SLC7A5—epithelium—uterine cancer	0.00505	0.0222	CbGeAlD
L-DOPA—SLC7A5—uterine cervix—uterine cancer	0.00501	0.022	CbGeAlD
L-DOPA—SLC7A5—smooth muscle tissue—uterine cancer	0.00487	0.0214	CbGeAlD
L-DOPA—SLC7A8—female reproductive system—uterine cancer	0.00484	0.0213	CbGeAlD
L-DOPA—SLC7A5—decidua—uterine cancer	0.00477	0.0209	CbGeAlD
L-DOPA—SLC7A5—endometrium—uterine cancer	0.00453	0.0199	CbGeAlD
L-DOPA—SLC7A8—female gonad—uterine cancer	0.00441	0.0193	CbGeAlD
L-DOPA—SLC7A5—mammalian vulva—uterine cancer	0.00438	0.0192	CbGeAlD
L-DOPA—SLC7A8—vagina—uterine cancer	0.00438	0.0192	CbGeAlD
L-DOPA—PSIP1—lymph node—uterine cancer	0.0043	0.0189	CbGeAlD
L-DOPA—SLC15A1—epithelium—uterine cancer	0.00419	0.0184	CbGeAlD
L-DOPA—DDC—female reproductive system—uterine cancer	0.00419	0.0184	CbGeAlD
L-DOPA—SLC7A5—uterus—uterine cancer	0.00417	0.0183	CbGeAlD
L-DOPA—DRD5—female reproductive system—uterine cancer	0.00403	0.0177	CbGeAlD
L-DOPA—SLC15A1—renal system—uterine cancer	0.00389	0.0171	CbGeAlD
L-DOPA—SLC16A10—epithelium—uterine cancer	0.00387	0.017	CbGeAlD
L-DOPA—SLC15A1—endometrium—uterine cancer	0.00376	0.0165	CbGeAlD
L-DOPA—SLC7A5—female reproductive system—uterine cancer	0.00375	0.0165	CbGeAlD
L-DOPA—DRD5—female gonad—uterine cancer	0.00367	0.0161	CbGeAlD
L-DOPA—SLC15A1—mammalian vulva—uterine cancer	0.00364	0.016	CbGeAlD
L-DOPA—SLC7A5—female gonad—uterine cancer	0.00341	0.015	CbGeAlD
L-DOPA—SLC7A5—vagina—uterine cancer	0.00339	0.0149	CbGeAlD
L-DOPA—SLC16A10—mammalian vulva—uterine cancer	0.00335	0.0147	CbGeAlD
L-DOPA—SLC16A10—female reproductive system—uterine cancer	0.00287	0.0126	CbGeAlD
L-DOPA—SLC7A8—lymph node—uterine cancer	0.00283	0.0124	CbGeAlD
L-DOPA—SLC15A1—vagina—uterine cancer	0.00282	0.0124	CbGeAlD
L-DOPA—SLC16A10—vagina—uterine cancer	0.0026	0.0114	CbGeAlD
L-DOPA—DDC—lymph node—uterine cancer	0.00245	0.0108	CbGeAlD
L-DOPA—PSIP1—Levonorgestrel—Progesterone—uterine cancer	0.00237	0.156	CbGdCrCtD
L-DOPA—SLC7A5—lymph node—uterine cancer	0.0022	0.00963	CbGeAlD
L-DOPA—Masoprocol—CYP19A1—uterine cancer	0.00205	0.111	CrCbGaD
L-DOPA—SLC16A10—lymph node—uterine cancer	0.00168	0.00738	CbGeAlD
L-DOPA—CYP2D6—renal system—uterine cancer	0.00136	0.00599	CbGeAlD
L-DOPA—CYP2D6—female reproductive system—uterine cancer	0.00109	0.0048	CbGeAlD
L-DOPA—CYP2D6—female gonad—uterine cancer	0.000994	0.00436	CbGeAlD
L-DOPA—Urinary tract disorder—Etoposide—uterine cancer	0.000784	0.00166	CcSEcCtD
L-DOPA—Pruritus—Progesterone—uterine cancer	0.00078	0.00165	CcSEcCtD
L-DOPA—Oedema—Dactinomycin—uterine cancer	0.000779	0.00165	CcSEcCtD
L-DOPA—Urethral disorder—Etoposide—uterine cancer	0.000778	0.00164	CcSEcCtD
L-DOPA—Blood urea increased—Doxorubicin—uterine cancer	0.000774	0.00164	CcSEcCtD
L-DOPA—Thrombocytopenia—Dactinomycin—uterine cancer	0.000763	0.00161	CcSEcCtD
L-DOPA—Diarrhoea—Progesterone—uterine cancer	0.000754	0.00159	CcSEcCtD
L-DOPA—Phlebitis—Epirubicin—uterine cancer	0.000747	0.00158	CcSEcCtD
L-DOPA—Anorexia—Dactinomycin—uterine cancer	0.000743	0.00157	CcSEcCtD
L-DOPA—Flushing—Etoposide—uterine cancer	0.000737	0.00156	CcSEcCtD
L-DOPA—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000736	0.00155	CcSEcCtD
L-DOPA—Dizziness—Progesterone—uterine cancer	0.000729	0.00154	CcSEcCtD
L-DOPA—Vascular purpura—Epirubicin—uterine cancer	0.000719	0.00152	CcSEcCtD
L-DOPA—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000717	0.00151	CcSEcCtD
L-DOPA—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000707	0.00149	CcSEcCtD
L-DOPA—Alopecia—Etoposide—uterine cancer	0.000701	0.00148	CcSEcCtD
L-DOPA—Vomiting—Progesterone—uterine cancer	0.000701	0.00148	CcSEcCtD
L-DOPA—Rash—Progesterone—uterine cancer	0.000695	0.00147	CcSEcCtD
L-DOPA—Dermatitis—Progesterone—uterine cancer	0.000694	0.00147	CcSEcCtD
L-DOPA—Phlebitis—Doxorubicin—uterine cancer	0.000691	0.00146	CcSEcCtD
L-DOPA—Headache—Progesterone—uterine cancer	0.000691	0.00146	CcSEcCtD
L-DOPA—Hot flush—Epirubicin—uterine cancer	0.000688	0.00145	CcSEcCtD
L-DOPA—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000683	0.00144	CcSEcCtD
L-DOPA—Menopausal symptoms—Epirubicin—uterine cancer	0.000682	0.00144	CcSEcCtD
L-DOPA—Decreased appetite—Dactinomycin—uterine cancer	0.000677	0.00143	CcSEcCtD
L-DOPA—Dysgeusia—Etoposide—uterine cancer	0.000677	0.00143	CcSEcCtD
L-DOPA—Dermatitis bullous—Epirubicin—uterine cancer	0.000673	0.00142	CcSEcCtD
L-DOPA—Fatigue—Dactinomycin—uterine cancer	0.000672	0.00142	CcSEcCtD
L-DOPA—Back pain—Etoposide—uterine cancer	0.000668	0.00141	CcSEcCtD
L-DOPA—Purpura—Epirubicin—uterine cancer	0.000667	0.00141	CcSEcCtD
L-DOPA—Pain—Dactinomycin—uterine cancer	0.000666	0.00141	CcSEcCtD
L-DOPA—Vascular purpura—Doxorubicin—uterine cancer	0.000665	0.00141	CcSEcCtD
L-DOPA—Muscle spasms—Etoposide—uterine cancer	0.000664	0.0014	CcSEcCtD
L-DOPA—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000661	0.0014	CcSEcCtD
L-DOPA—Nausea—Progesterone—uterine cancer	0.000655	0.00138	CcSEcCtD
L-DOPA—Diplopia—Epirubicin—uterine cancer	0.000643	0.00136	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000643	0.00136	CcSEcCtD
L-DOPA—Pain in extremity—Epirubicin—uterine cancer	0.000643	0.00136	CcSEcCtD
L-DOPA—Feeling abnormal—Dactinomycin—uterine cancer	0.000642	0.00136	CcSEcCtD
L-DOPA—Ill-defined disorder—Etoposide—uterine cancer	0.000641	0.00135	CcSEcCtD
L-DOPA—Anaemia—Etoposide—uterine cancer	0.000639	0.00135	CcSEcCtD
L-DOPA—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000637	0.00135	CcSEcCtD
L-DOPA—Hot flush—Doxorubicin—uterine cancer	0.000636	0.00134	CcSEcCtD
L-DOPA—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000635	0.00134	CcSEcCtD
L-DOPA—Menopausal symptoms—Doxorubicin—uterine cancer	0.000631	0.00133	CcSEcCtD
L-DOPA—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00063	0.00133	CcSEcCtD
L-DOPA—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000629	0.00133	CcSEcCtD
L-DOPA—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000626	0.00132	CcSEcCtD
L-DOPA—Malaise—Etoposide—uterine cancer	0.000623	0.00132	CcSEcCtD
L-DOPA—Dermatitis bullous—Doxorubicin—uterine cancer	0.000623	0.00132	CcSEcCtD
L-DOPA—Leukopenia—Etoposide—uterine cancer	0.000618	0.00131	CcSEcCtD
L-DOPA—Purpura—Doxorubicin—uterine cancer	0.000617	0.0013	CcSEcCtD
L-DOPA—Abdominal pain—Dactinomycin—uterine cancer	0.000616	0.0013	CcSEcCtD
L-DOPA—Loss of consciousness—Etoposide—uterine cancer	0.000607	0.00128	CcSEcCtD
L-DOPA—Ataxia—Epirubicin—uterine cancer	0.000605	0.00128	CcSEcCtD
L-DOPA—Cough—Etoposide—uterine cancer	0.000603	0.00127	CcSEcCtD
L-DOPA—Blood creatinine increased—Epirubicin—uterine cancer	0.000603	0.00127	CcSEcCtD
L-DOPA—Convulsion—Etoposide—uterine cancer	0.000599	0.00126	CcSEcCtD
L-DOPA—Hypertension—Etoposide—uterine cancer	0.000597	0.00126	CcSEcCtD
L-DOPA—Pain in extremity—Doxorubicin—uterine cancer	0.000595	0.00126	CcSEcCtD
L-DOPA—Diplopia—Doxorubicin—uterine cancer	0.000595	0.00126	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000595	0.00126	CcSEcCtD
L-DOPA—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000593	0.00125	CcSEcCtD
L-DOPA—Chest pain—Etoposide—uterine cancer	0.000588	0.00124	CcSEcCtD
L-DOPA—Orthostatic hypotension—Epirubicin—uterine cancer	0.000587	0.00124	CcSEcCtD
L-DOPA—Discomfort—Etoposide—uterine cancer	0.000581	0.00123	CcSEcCtD
L-DOPA—Nasopharyngitis—Epirubicin—uterine cancer	0.000575	0.00121	CcSEcCtD
L-DOPA—Hypersensitivity—Dactinomycin—uterine cancer	0.000574	0.00121	CcSEcCtD
L-DOPA—Gastritis—Epirubicin—uterine cancer	0.000569	0.0012	CcSEcCtD
L-DOPA—Confusional state—Etoposide—uterine cancer	0.000569	0.0012	CcSEcCtD
L-DOPA—Ataxia—Doxorubicin—uterine cancer	0.00056	0.00118	CcSEcCtD
L-DOPA—Asthenia—Dactinomycin—uterine cancer	0.000559	0.00118	CcSEcCtD
L-DOPA—Blood creatinine increased—Doxorubicin—uterine cancer	0.000557	0.00118	CcSEcCtD
L-DOPA—Dysphagia—Epirubicin—uterine cancer	0.000556	0.00117	CcSEcCtD
L-DOPA—Thrombocytopenia—Etoposide—uterine cancer	0.000552	0.00117	CcSEcCtD
L-DOPA—Hyperhidrosis—Etoposide—uterine cancer	0.000545	0.00115	CcSEcCtD
L-DOPA—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000544	0.00115	CcSEcCtD
L-DOPA—Angina pectoris—Epirubicin—uterine cancer	0.000541	0.00114	CcSEcCtD
L-DOPA—Anorexia—Etoposide—uterine cancer	0.000538	0.00114	CcSEcCtD
L-DOPA—Diarrhoea—Dactinomycin—uterine cancer	0.000533	0.00113	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—uterine cancer	0.000532	0.00112	CcSEcCtD
L-DOPA—Hypotension—Etoposide—uterine cancer	0.000527	0.00111	CcSEcCtD
L-DOPA—Gastritis—Doxorubicin—uterine cancer	0.000527	0.00111	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000517	0.00109	CcSEcCtD
L-DOPA—Dysphagia—Doxorubicin—uterine cancer	0.000514	0.00109	CcSEcCtD
L-DOPA—Pollakiuria—Epirubicin—uterine cancer	0.000514	0.00108	CcSEcCtD
L-DOPA—Paraesthesia—Etoposide—uterine cancer	0.000506	0.00107	CcSEcCtD
L-DOPA—Weight increased—Epirubicin—uterine cancer	0.000506	0.00107	CcSEcCtD
L-DOPA—Weight decreased—Epirubicin—uterine cancer	0.000503	0.00106	CcSEcCtD
L-DOPA—Dyspnoea—Etoposide—uterine cancer	0.000503	0.00106	CcSEcCtD
L-DOPA—Somnolence—Etoposide—uterine cancer	0.000501	0.00106	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—uterine cancer	0.000501	0.00106	CcSEcCtD
L-DOPA—Vomiting—Dactinomycin—uterine cancer	0.000495	0.00105	CcSEcCtD
L-DOPA—Rash—Dactinomycin—uterine cancer	0.000491	0.00104	CcSEcCtD
L-DOPA—Decreased appetite—Etoposide—uterine cancer	0.00049	0.00104	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Etoposide—uterine cancer	0.000487	0.00103	CcSEcCtD
L-DOPA—Fatigue—Etoposide—uterine cancer	0.000486	0.00103	CcSEcCtD
L-DOPA—Neuropathy peripheral—Epirubicin—uterine cancer	0.000486	0.00103	CcSEcCtD
L-DOPA—Pain—Etoposide—uterine cancer	0.000482	0.00102	CcSEcCtD
L-DOPA—Constipation—Etoposide—uterine cancer	0.000482	0.00102	CcSEcCtD
L-DOPA—Urinary tract infection—Epirubicin—uterine cancer	0.000482	0.00102	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000478	0.00101	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—uterine cancer	0.000475	0.001	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—uterine cancer	0.000468	0.000989	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—uterine cancer	0.000465	0.000983	CcSEcCtD
L-DOPA—Feeling abnormal—Etoposide—uterine cancer	0.000465	0.000982	CcSEcCtD
L-DOPA—Nausea—Dactinomycin—uterine cancer	0.000463	0.000978	CcSEcCtD
L-DOPA—Agranulocytosis—Epirubicin—uterine cancer	0.000463	0.000977	CcSEcCtD
L-DOPA—Gastrointestinal pain—Etoposide—uterine cancer	0.000461	0.000974	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—uterine cancer	0.00045	0.00095	CcSEcCtD
L-DOPA—Urticaria—Etoposide—uterine cancer	0.000448	0.000946	CcSEcCtD
L-DOPA—Haemoglobin—Epirubicin—uterine cancer	0.000447	0.000945	CcSEcCtD
L-DOPA—Rhinitis—Epirubicin—uterine cancer	0.000446	0.000942	CcSEcCtD
L-DOPA—Abdominal pain—Etoposide—uterine cancer	0.000446	0.000942	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—uterine cancer	0.000446	0.000942	CcSEcCtD
L-DOPA—Haemorrhage—Epirubicin—uterine cancer	0.000445	0.00094	CcSEcCtD
L-DOPA—Hypoaesthesia—Epirubicin—uterine cancer	0.000443	0.000935	CcSEcCtD
L-DOPA—Urinary tract disorder—Epirubicin—uterine cancer	0.000439	0.000928	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—uterine cancer	0.000436	0.000921	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—uterine cancer	0.000428	0.000904	CcSEcCtD
L-DOPA—Hypersensitivity—Etoposide—uterine cancer	0.000415	0.000878	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—uterine cancer	0.000414	0.000874	CcSEcCtD
L-DOPA—Flushing—Epirubicin—uterine cancer	0.000413	0.000872	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—uterine cancer	0.000413	0.000872	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—uterine cancer	0.000412	0.00087	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—uterine cancer	0.00041	0.000865	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—uterine cancer	0.000407	0.000859	CcSEcCtD
L-DOPA—Asthenia—Etoposide—uterine cancer	0.000405	0.000855	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—uterine cancer	0.000404	0.000853	CcSEcCtD
L-DOPA—Pruritus—Etoposide—uterine cancer	0.000399	0.000843	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—uterine cancer	0.000397	0.00084	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—uterine cancer	0.000393	0.000831	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—uterine cancer	0.00039	0.000823	CcSEcCtD
L-DOPA—Diarrhoea—Etoposide—uterine cancer	0.000386	0.000815	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—uterine cancer	0.000382	0.000807	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—uterine cancer	0.000382	0.000806	CcSEcCtD
L-DOPA—Tension—Epirubicin—uterine cancer	0.00038	0.000803	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—uterine cancer	0.000379	0.000801	CcSEcCtD
L-DOPA—Nervousness—Epirubicin—uterine cancer	0.000376	0.000795	CcSEcCtD
L-DOPA—Back pain—Epirubicin—uterine cancer	0.000375	0.000791	CcSEcCtD
L-DOPA—Dizziness—Etoposide—uterine cancer	0.000373	0.000788	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—uterine cancer	0.000372	0.000787	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—uterine cancer	0.000368	0.000777	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—uterine cancer	0.000365	0.000771	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—uterine cancer	0.000364	0.000769	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—uterine cancer	0.000361	0.000762	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—uterine cancer	0.000359	0.000759	CcSEcCtD
L-DOPA—Vomiting—Etoposide—uterine cancer	0.000359	0.000757	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—uterine cancer	0.000358	0.000756	CcSEcCtD
L-DOPA—Agitation—Epirubicin—uterine cancer	0.000356	0.000752	CcSEcCtD
L-DOPA—Rash—Etoposide—uterine cancer	0.000356	0.000751	CcSEcCtD
L-DOPA—Dermatitis—Etoposide—uterine cancer	0.000355	0.00075	CcSEcCtD
L-DOPA—Headache—Etoposide—uterine cancer	0.000353	0.000746	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—uterine cancer	0.000353	0.000746	CcSEcCtD
L-DOPA—Tension—Doxorubicin—uterine cancer	0.000352	0.000743	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—uterine cancer	0.000351	0.000741	CcSEcCtD
L-DOPA—Malaise—Epirubicin—uterine cancer	0.000349	0.000738	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—uterine cancer	0.000348	0.000735	CcSEcCtD
L-DOPA—Syncope—Epirubicin—uterine cancer	0.000347	0.000734	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—uterine cancer	0.000347	0.000732	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—uterine cancer	0.000347	0.000732	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—uterine cancer	0.000345	0.000728	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—uterine cancer	0.000342	0.000723	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—uterine cancer	0.00034	0.000719	CcSEcCtD
L-DOPA—Cough—Epirubicin—uterine cancer	0.000338	0.000714	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—uterine cancer	0.000338	0.000713	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—uterine cancer	0.000336	0.000709	CcSEcCtD
L-DOPA—Nausea—Etoposide—uterine cancer	0.000335	0.000708	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—uterine cancer	0.000334	0.000706	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—uterine cancer	0.000333	0.000702	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—uterine cancer	0.000331	0.0007	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—uterine cancer	0.00033	0.000697	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—uterine cancer	0.000329	0.000696	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—uterine cancer	0.000329	0.000694	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—uterine cancer	0.000326	0.000688	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—uterine cancer	0.000323	0.000683	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—uterine cancer	0.000322	0.000681	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—uterine cancer	0.000321	0.000679	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—uterine cancer	0.000321	0.000678	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—uterine cancer	0.000319	0.000673	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—uterine cancer	0.000317	0.000669	CcSEcCtD
L-DOPA—Oedema—Epirubicin—uterine cancer	0.000316	0.000668	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—uterine cancer	0.000315	0.000665	CcSEcCtD
L-DOPA—Cough—Doxorubicin—uterine cancer	0.000313	0.000661	CcSEcCtD
L-DOPA—Shock—Epirubicin—uterine cancer	0.000311	0.000657	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—uterine cancer	0.000311	0.000656	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—uterine cancer	0.000309	0.000654	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—uterine cancer	0.000309	0.000654	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—uterine cancer	0.000306	0.000646	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—uterine cancer	0.000305	0.000645	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—uterine cancer	0.000304	0.000642	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—uterine cancer	0.000301	0.000637	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—uterine cancer	0.000301	0.000637	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—uterine cancer	0.000298	0.00063	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—uterine cancer	0.000295	0.000624	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—uterine cancer	0.000295	0.000623	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—uterine cancer	0.000292	0.000618	CcSEcCtD
L-DOPA—Shock—Doxorubicin—uterine cancer	0.000288	0.000608	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—uterine cancer	0.000286	0.000605	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—uterine cancer	0.000286	0.000604	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—uterine cancer	0.000284	0.0006	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—uterine cancer	0.000283	0.000597	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—uterine cancer	0.000282	0.000595	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—uterine cancer	0.000281	0.000594	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—uterine cancer	0.000279	0.000589	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—uterine cancer	0.000278	0.000588	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—uterine cancer	0.000275	0.00058	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—uterine cancer	0.000273	0.000577	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000273	0.000577	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—uterine cancer	0.000273	0.000576	CcSEcCtD
L-DOPA—Constipation—Epirubicin—uterine cancer	0.00027	0.000571	CcSEcCtD
L-DOPA—Pain—Epirubicin—uterine cancer	0.00027	0.000571	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—uterine cancer	0.000265	0.000559	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—uterine cancer	0.000263	0.000555	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—uterine cancer	0.000261	0.000551	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—uterine cancer	0.00026	0.00055	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—uterine cancer	0.00026	0.000549	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—uterine cancer	0.000258	0.000546	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—uterine cancer	0.000257	0.000544	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—uterine cancer	0.000254	0.000537	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000253	0.000533	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—uterine cancer	0.000252	0.000533	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—uterine cancer	0.000251	0.00053	CcSEcCtD
L-DOPA—Pain—Doxorubicin—uterine cancer	0.00025	0.000528	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—uterine cancer	0.00025	0.000528	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—uterine cancer	0.00025	0.000528	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—uterine cancer	0.000241	0.000509	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000239	0.000505	CcSEcCtD
L-DOPA—Hypersensitivity—Epirubicin—uterine cancer	0.000233	0.000492	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—uterine cancer	0.000232	0.000491	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—uterine cancer	0.000231	0.000488	CcSEcCtD
L-DOPA—Asthenia—Epirubicin—uterine cancer	0.000227	0.000479	CcSEcCtD
L-DOPA—Pruritus—Epirubicin—uterine cancer	0.000224	0.000472	CcSEcCtD
L-DOPA—Diarrhoea—Epirubicin—uterine cancer	0.000216	0.000457	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—uterine cancer	0.000215	0.000455	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—uterine cancer	0.00021	0.000443	CcSEcCtD
L-DOPA—Dizziness—Epirubicin—uterine cancer	0.000209	0.000442	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—uterine cancer	0.000207	0.000437	CcSEcCtD
L-DOPA—Vomiting—Epirubicin—uterine cancer	0.000201	0.000425	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—uterine cancer	0.0002	0.000423	CcSEcCtD
L-DOPA—Rash—Epirubicin—uterine cancer	0.000199	0.000421	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—uterine cancer	0.000199	0.000421	CcSEcCtD
L-DOPA—Headache—Epirubicin—uterine cancer	0.000198	0.000418	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—uterine cancer	0.000193	0.000409	CcSEcCtD
L-DOPA—Nausea—Epirubicin—uterine cancer	0.000188	0.000397	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—uterine cancer	0.000186	0.000393	CcSEcCtD
L-DOPA—Rash—Doxorubicin—uterine cancer	0.000184	0.00039	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—uterine cancer	0.000184	0.000389	CcSEcCtD
L-DOPA—Headache—Doxorubicin—uterine cancer	0.000183	0.000387	CcSEcCtD
L-DOPA—Nausea—Doxorubicin—uterine cancer	0.000174	0.000367	CcSEcCtD
L-DOPA—DRD5—Signaling Pathways—AKR1C1—uterine cancer	0.000139	0.000525	CbGpPWpGaD
L-DOPA—PSIP1—Disease—NRAS—uterine cancer	0.000139	0.000524	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—CXCL8—uterine cancer	0.000139	0.000522	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—HRAS—uterine cancer	0.000137	0.000516	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—EP300—uterine cancer	0.000136	0.000515	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKR1B10—uterine cancer	0.000135	0.000511	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—EP300—uterine cancer	0.000135	0.000508	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKR1B10—uterine cancer	0.000134	0.000504	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—PIK3CA—uterine cancer	0.000129	0.000487	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CXCL8—uterine cancer	0.000128	0.000483	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CYP19A1—uterine cancer	0.000127	0.000479	CbGpPWpGaD
L-DOPA—DDC—Metabolism—STK11—uterine cancer	0.000127	0.000479	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TP53—uterine cancer	0.000125	0.000471	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RNF43—uterine cancer	0.000125	0.00047	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000124	0.000468	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—AKT1—uterine cancer	0.000121	0.000456	CbGpPWpGaD
L-DOPA—PSIP1—Disease—KRAS—uterine cancer	0.00012	0.000451	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—HRAS—uterine cancer	0.000119	0.000451	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CCL2—uterine cancer	0.000119	0.00045	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—INHBA—uterine cancer	0.000114	0.00043	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RNF43—uterine cancer	0.000112	0.000423	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000112	0.000421	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RNF43—uterine cancer	0.000111	0.000418	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.00011	0.000415	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PIK3CA—uterine cancer	0.00011	0.000414	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—uterine cancer	0.000108	0.000409	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—PTEN—uterine cancer	0.000108	0.000407	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CCL2—uterine cancer	0.000108	0.000406	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKR1C3—uterine cancer	0.000107	0.000404	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000107	0.000402	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CCL2—uterine cancer	0.000106	0.0004	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CXCL8—uterine cancer	0.000106	0.0004	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—AKT1—uterine cancer	0.000105	0.000398	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PGR—uterine cancer	0.000104	0.000394	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—EP300—uterine cancer	0.000103	0.000389	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKR1C1—uterine cancer	0.000103	0.000387	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—INHBA—uterine cancer	0.000103	0.000387	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKR1B10—uterine cancer	0.000102	0.000386	CbGpPWpGaD
L-DOPA—PSIP1—Disease—HRAS—uterine cancer	0.000102	0.000383	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—INHBA—uterine cancer	0.000101	0.000382	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—YWHAE—uterine cancer	9.95e-05	0.000375	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—uterine cancer	9.76e-05	0.000368	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—uterine cancer	9.63e-05	0.000363	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FBXW7—uterine cancer	9.54e-05	0.00036	CbGpPWpGaD
L-DOPA—DDC—Metabolism—MTHFR—uterine cancer	9.54e-05	0.00036	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CXCL8—uterine cancer	9.44e-05	0.000356	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKR1C1—uterine cancer	9.24e-05	0.000349	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SRD5A2—uterine cancer	9.17e-05	0.000346	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NDUFB11—uterine cancer	9.17e-05	0.000346	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKR1C1—uterine cancer	9.12e-05	0.000344	CbGpPWpGaD
L-DOPA—PSIP1—Disease—AKT1—uterine cancer	8.97e-05	0.000338	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CXCL8—uterine cancer	8.5e-05	0.000321	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RNF43—uterine cancer	8.47e-05	0.00032	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	8.43e-05	0.000318	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CXCL8—uterine cancer	8.39e-05	0.000316	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STK11—uterine cancer	8.34e-05	0.000315	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CCL2—uterine cancer	8.3e-05	0.000313	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CCL2—uterine cancer	8.12e-05	0.000306	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKR1C3—uterine cancer	7.9e-05	0.000298	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SOCS3—uterine cancer	7.81e-05	0.000295	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—INHBA—uterine cancer	7.75e-05	0.000292	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PGR—uterine cancer	7.7e-05	0.000291	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN2B—uterine cancer	7.48e-05	0.000282	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—uterine cancer	7.37e-05	0.000278	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—YWHAE—uterine cancer	7.35e-05	0.000277	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IGF1R—uterine cancer	7.26e-05	0.000274	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CXCL8—uterine cancer	7.23e-05	0.000273	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKR1C3—uterine cancer	7.11e-05	0.000268	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FBXW7—uterine cancer	7.04e-05	0.000266	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKR1C3—uterine cancer	7.02e-05	0.000265	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKR1C1—uterine cancer	6.98e-05	0.000263	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PGR—uterine cancer	6.93e-05	0.000262	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PGR—uterine cancer	6.84e-05	0.000258	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SMAD3—uterine cancer	6.83e-05	0.000258	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—STAR—uterine cancer	6.63e-05	0.00025	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKR1B1—uterine cancer	6.63e-05	0.00025	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—YWHAE—uterine cancer	6.61e-05	0.000249	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CXCL8—uterine cancer	6.57e-05	0.000248	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—YWHAE—uterine cancer	6.53e-05	0.000246	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FGFR2—uterine cancer	6.51e-05	0.000246	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CXCL8—uterine cancer	6.42e-05	0.000242	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FBXW7—uterine cancer	6.34e-05	0.000239	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FBXW7—uterine cancer	6.26e-05	0.000236	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STK11—uterine cancer	6.16e-05	0.000232	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCL2—uterine cancer	6.13e-05	0.000231	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SOCS3—uterine cancer	5.77e-05	0.000217	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ESR1—uterine cancer	5.57e-05	0.00021	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STK11—uterine cancer	5.54e-05	0.000209	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN2B—uterine cancer	5.52e-05	0.000208	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCL2—uterine cancer	5.52e-05	0.000208	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STK11—uterine cancer	5.47e-05	0.000206	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCL2—uterine cancer	5.44e-05	0.000205	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKR1C3—uterine cancer	5.37e-05	0.000203	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1R—uterine cancer	5.36e-05	0.000202	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCL8—uterine cancer	5.34e-05	0.000201	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTEN—uterine cancer	5.31e-05	0.0002	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—NRAS—uterine cancer	5.27e-05	0.000199	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PGR—uterine cancer	5.23e-05	0.000197	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—POLD1—uterine cancer	5.2e-05	0.000196	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SOCS3—uterine cancer	5.19e-05	0.000196	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SOCS3—uterine cancer	5.12e-05	0.000193	CbGpPWpGaD
L-DOPA—DDC—Metabolism—EP300—uterine cancer	5.06e-05	0.000191	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SMAD3—uterine cancer	5.04e-05	0.00019	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—YWHAE—uterine cancer	4.99e-05	0.000188	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN2B—uterine cancer	4.97e-05	0.000187	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL2—uterine cancer	4.91e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN2B—uterine cancer	4.9e-05	0.000185	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKR1C1—uterine cancer	4.87e-05	0.000184	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL8—uterine cancer	4.85e-05	0.000183	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1R—uterine cancer	4.83e-05	0.000182	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FGFR2—uterine cancer	4.81e-05	0.000181	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL8—uterine cancer	4.8e-05	0.000181	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FBXW7—uterine cancer	4.79e-05	0.000181	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1R—uterine cancer	4.76e-05	0.00018	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL8—uterine cancer	4.74e-05	0.000179	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—PIK3CA—uterine cancer	4.59e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SMAD3—uterine cancer	4.54e-05	0.000171	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—KRAS—uterine cancer	4.53e-05	0.000171	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SMAD3—uterine cancer	4.48e-05	0.000169	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL8—uterine cancer	4.36e-05	0.000165	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—RRM2—uterine cancer	4.34e-05	0.000164	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FGFR2—uterine cancer	4.33e-05	0.000163	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL8—uterine cancer	4.3e-05	0.000162	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FGFR2—uterine cancer	4.27e-05	0.000161	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—DCN—uterine cancer	4.21e-05	0.000159	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STK11—uterine cancer	4.18e-05	0.000158	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL2—uterine cancer	4.17e-05	0.000157	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PIK3CA—uterine cancer	4.16e-05	0.000157	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ESR1—uterine cancer	4.11e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ERBB2—uterine cancer	4.09e-05	0.000154	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP11A1—uterine cancer	3.97e-05	0.00015	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SOCS3—uterine cancer	3.92e-05	0.000148	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—NRAS—uterine cancer	3.89e-05	0.000147	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL8—uterine cancer	3.88e-05	0.000146	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HRAS—uterine cancer	3.85e-05	0.000145	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN1B—uterine cancer	3.79e-05	0.000143	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN2B—uterine cancer	3.75e-05	0.000142	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKR1C3—uterine cancer	3.75e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—uterine cancer	3.75e-05	0.000141	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PIK3CA—uterine cancer	3.74e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ESR1—uterine cancer	3.7e-05	0.00014	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ESR1—uterine cancer	3.65e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1R—uterine cancer	3.64e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—uterine cancer	3.63e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL2—uterine cancer	3.62e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CTNNB1—uterine cancer	3.58e-05	0.000135	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—NRAS—uterine cancer	3.5e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTEN—uterine cancer	3.49e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—NRAS—uterine cancer	3.45e-05	0.00013	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SMAD3—uterine cancer	3.43e-05	0.000129	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—uterine cancer	3.4e-05	0.000128	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—uterine cancer	3.38e-05	0.000128	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—uterine cancer	3.35e-05	0.000126	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EP300—uterine cancer	3.33e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—uterine cancer	3.29e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGFR2—uterine cancer	3.27e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL2—uterine cancer	3.26e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL2—uterine cancer	3.22e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—uterine cancer	3.15e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NRAS—uterine cancer	3.11e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—uterine cancer	3.07e-05	0.000116	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—uterine cancer	3.06e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—uterine cancer	3.05e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—uterine cancer	3.02e-05	0.000114	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—uterine cancer	3.01e-05	0.000114	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—uterine cancer	3.01e-05	0.000113	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—uterine cancer	2.97e-05	0.000112	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—STK11—uterine cancer	2.92e-05	0.00011	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP19A1—uterine cancer	2.92e-05	0.00011	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—uterine cancer	2.86e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—uterine cancer	2.84e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1B—uterine cancer	2.8e-05	0.000105	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ESR1—uterine cancer	2.8e-05	0.000105	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—uterine cancer	2.77e-05	0.000104	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—uterine cancer	2.77e-05	0.000104	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—uterine cancer	2.73e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—uterine cancer	2.72e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—uterine cancer	2.68e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—uterine cancer	2.68e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—NRAS—uterine cancer	2.64e-05	9.97e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CTNNB1—uterine cancer	2.64e-05	9.96e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—uterine cancer	2.58e-05	9.72e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTEN—uterine cancer	2.57e-05	9.71e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—uterine cancer	2.56e-05	9.66e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—uterine cancer	2.54e-05	9.59e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—uterine cancer	2.53e-05	9.53e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1B—uterine cancer	2.52e-05	9.49e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—uterine cancer	2.51e-05	9.47e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—uterine cancer	2.49e-05	9.39e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1B—uterine cancer	2.48e-05	9.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL2—uterine cancer	2.46e-05	9.28e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—uterine cancer	2.46e-05	9.28e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—uterine cancer	2.46e-05	9.26e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EP300—uterine cancer	2.45e-05	9.26e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—uterine cancer	2.38e-05	8.98e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CTNNB1—uterine cancer	2.38e-05	8.97e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CTNNB1—uterine cancer	2.35e-05	8.85e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—uterine cancer	2.32e-05	8.77e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTEN—uterine cancer	2.32e-05	8.74e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—uterine cancer	2.3e-05	8.68e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NRAS—uterine cancer	2.3e-05	8.66e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTEN—uterine cancer	2.29e-05	8.62e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—uterine cancer	2.28e-05	8.59e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—uterine cancer	2.27e-05	8.58e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—uterine cancer	2.26e-05	8.53e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—uterine cancer	2.23e-05	8.41e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EP300—uterine cancer	2.21e-05	8.34e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTHFR—uterine cancer	2.19e-05	8.27e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EP300—uterine cancer	2.18e-05	8.22e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—uterine cancer	2.09e-05	7.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—uterine cancer	2.09e-05	7.88e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NRAS—uterine cancer	2.07e-05	7.8e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—uterine cancer	2.06e-05	7.79e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—uterine cancer	2.05e-05	7.74e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NRAS—uterine cancer	2.04e-05	7.69e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—uterine cancer	2.01e-05	7.58e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—uterine cancer	1.98e-05	7.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—uterine cancer	1.95e-05	7.34e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—uterine cancer	1.93e-05	7.29e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1B—uterine cancer	1.9e-05	7.17e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—uterine cancer	1.88e-05	7.09e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—uterine cancer	1.82e-05	6.85e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CTNNB1—uterine cancer	1.79e-05	6.77e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—uterine cancer	1.78e-05	6.71e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—uterine cancer	1.76e-05	6.63e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—uterine cancer	1.76e-05	6.62e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTEN—uterine cancer	1.75e-05	6.6e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—uterine cancer	1.71e-05	6.44e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—uterine cancer	1.68e-05	6.34e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EP300—uterine cancer	1.67e-05	6.29e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—uterine cancer	1.63e-05	6.17e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—uterine cancer	1.61e-05	6.08e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—uterine cancer	1.58e-05	5.96e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—uterine cancer	1.58e-05	5.96e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NRAS—uterine cancer	1.56e-05	5.89e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—uterine cancer	1.56e-05	5.89e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—uterine cancer	1.51e-05	5.7e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—uterine cancer	1.49e-05	5.63e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—uterine cancer	1.48e-05	5.6e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—uterine cancer	1.34e-05	5.07e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—uterine cancer	1.34e-05	5.04e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—uterine cancer	1.32e-05	4.97e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—uterine cancer	1.23e-05	4.66e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTEN—uterine cancer	1.22e-05	4.6e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—uterine cancer	1.19e-05	4.5e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—EP300—uterine cancer	1.16e-05	4.39e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—uterine cancer	1.14e-05	4.31e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—uterine cancer	1.01e-05	3.8e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—uterine cancer	8.61e-06	3.25e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—uterine cancer	7.03e-06	2.65e-05	CbGpPWpGaD
